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There is nothing ‘incidental’ about unrelated 
findings
unrelated case of idiopathic hemolytic anemia. 
As these results were not Clinical Laboratory 
Improvement Amendments (CLIA) certified, 
I conveyed the anemia results to a physician 
of the research participant for validation and 
follow-up in a CLIA-certified environment. 
I grappled with the very difficult ethical and 
moral need to pursue the genetic basis of dis-
orders unrelated to the primary research pur-
pose, particularly when one finds out about such 
disorders after the sequencing has commenced. 
Hank Greely has argued forcefully that any-
one participating in a genetics research study is 
protected by the human subjects research poli-
cies, including the ethical and moral need to 
pursue and return unrelated findings to such 
participants [5]. Given that I agree that the col-
lection and sequencing of families falls squarely 
in the area of human subjects research, I have 
suggested here and elsewhere that researchers 
consider sequencing whole genomes in CLIA-
certified laboratories going forward, either at 
Complete Genomics (CA, USA), Illumina (CA, 
USA) or elsewhere, depending on the quality 
and price [6]. I have also discussed the need for 
CLIA certification in terms of the moral need to 
return ‘unrelated findings’ that can emerge dur-
ing such research [4,6]. I suggest herein that the 
genomics research community replace the term 
‘incidental findings’ with the term ‘unrelated 
findings’, given that there is nothing incidental 
about proving causality for any mutation.
An unrelated finding
As the cost of next-generation sequencing con-
tinues to decrease exponentially, it is becoming 
both affordable and relatively easy for many lab-
oratories, including those outside of large-scale 
sequencing centers, to perform exon capture, 
and eventually, whole-genome sequencing in 
The specific topic for discussion in this editorial 
concerns the nature of ‘unrelated findings’, along 
with suggestions for how such issues should be 
handled in the future. In addition to focusing 
on highly penetrant Mendelian disorders [1,2], 
I am focusing my research on childhood-onset 
neuropsychiatric disorders, including attention 
deficit hyperactivity disorder (ADHD), obses-
sive compulsive disorder, Tourette’s syndrome, 
developmental delay and mental retardation. 
After finishing clinical training in psychiatry, I 
moved to the state of Utah, USA in 2009, so that 
I could study large pedigrees for human genet-
ics there, given that families tend to be large in 
Utah and the genealogy records of the Mormon 
Church are quite extensive. Utah has therefore 
been, and continues to be, a very fertile ground 
for human genetics research, with perhaps the 
most famous genetics finding involving the 
cloning of the breast cancer gene, BRCA1 [3]. In 
2011, we published [1] and discussed elsewhere 
[2] our recent discovery in Utah of a new infan-
tile lethal disease, dubbed Ogden syndrome, in 
honor of the city where the first family lives. I 
would like to discuss here a more recent project, 
in which we have had to struggle with what we 
have termed ‘unrelated findings’ coming out of 
a whole-exome sequencing project performed on 
one family in Utah. 
In late 2009, we decided to apply exome 
sequencing to a complex disease, namely 
ADHD. Psychiatric genetics is a much harder 
problem than that of a fully penetrant infan-
tile lethal syndrome, and our paper was one 
of the first (to my knowledge), explicitly dis-
cussing how we actively pursued and then 
handled an unrelated finding arising from our 
study [4]. In this instance, in addition to iden-
tifying rare variants that might contribute to 
ADHD, we determined the genetic basis of an part of
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selected individuals. This is already revolution-
izing the discovery of the genetic basis of many 
disorders that had resisted conventional link-
age mapping efforts [7–10]. As a result, there is 
now an ongoing avalanche of human genome 
sequencing results, emanating from many lab-
oratories and from many different sequencing 
platforms. In 2009, I joined the institutional 
review board protocols at the University of 
Utah (UT, USA), which allowed me to collect 
research subjects for human genomics research. 
Over the course of the next year, along with 
my colleagues, I enrolled and consented many 
dozens of families for genetic research, focused 
primarily on simple Mendelian disorders and 
childhood-onset neuropsychiatric disorders.
During the course of research, I decided to 
perform exome sequencing on one family with 
a mother, father and two sons. As described in 
our paper, the father and two sons had a severe 
form of ADHD, with a very similar phenotype 
among them, including a similar response to a 
methylphenidate derivative in a double-blind 
placebo-controlled trial [4]. As we described in 
the paper, one of the sons informed me dur-
ing a routine research visit that he had recently 
had a splenectomy, apparently resulting from 
a case of idiopathic hemolytic anemia. Given 
that I had already sequenced his exome, I felt 
an ethical and moral obligation to analyze the 
exome data to see if we could explain why he 
might have this anemia. After many filtering 
steps, we discovered that this person was a com-
pound heterozygote for two mutations in PKLR, 
with both mutations having been seen one time 
before in combination with other mutations in 
separate individuals also with hemolytic ane-
mia. However, there was no person reported 
in the literature possessing both mutations in 
this particular compound heterozygote state, so 
it was difficult to know causality, particularly 
with this person’s unique genetic background 
and environmental influences (i.e., penetrance). 
Therefore, we performed blood and enzymatic 
activity assays to confirm that his anemia 
likely resulted from these mutations, and we 
published some of these data in our paper [4]. 
Unpublished testing also included biochemi-
cal affinity assays performed on packed red 
cell concentrates, prepared from the patient’s 
blood (after removal of white cells and plate-
lets), with results consistent with our conclusion 
that these mutations were causative for hemo-
lytic anemia. This was an unrelated finding in 
the sense that our initial research purpose was 
to understand the genetic basis of the ADHD, 
but we discovered something unrelated to this 
purpose during our research.
There are many scientists and ethicists that 
are using the term ‘incidental finding’ to refer 
to unrelated findings arising from genom-
ics research. This term, ‘incidental finding’ 
is mostly used in the radiology field, where 
highly trained radiologists look at a film or 
image and recognize something outside the 
range of ‘normal’ but unrelated to the clini-
cal question, which they sometime refer to as 
an ‘incidental’ or ‘coincidental finding’ [11,12]. 
A PubMed search in November 2011 for the 
term ‘incidental findings’ returns references 
to a mind boggling 12,788 papers, of which 
4027 are encompassed within the subsearch of 
‘incidental findings AND radiology’. On the 
other hand, a PubMed search for ‘incidental 
findings AND genetics’ returns 543 papers, a 
number far less than in radiology, but which 
reflects the growing use of this term in the 
genetics community. Obviously, this is only a 
crude measure, given that even a casual inspec-
tion of the titles and abstracts for many of these 
genetics papers reveals an obvious connection 
still with radiology papers in the context of 
neuroimaging studies also involving genetics. 
One recent paper on the rate of ‘incidental 
findings’ in neuroimaging research showed 
that “of 1426 research imaging examinations, 
567 (39.8%) had at least one incidental finding 
(1055 total)” [13]. This is a staggering number, 
and the paper also went on to show that “of the 
567 examinations with an incidental finding, 
35 (6.2%) generated clinical action, resulting 
in clear medical benefit in 1.1% (6 of 567) and 
clear medical burden in 0.5% (3 of 567)” [13]. 
These are small but not trivial rates of benefit 
and detriment resulting from the investigation 
of these incidental findings.
“...I would suggest that the research 
community strongly consider getting rid of 
this term in the genomics world, and 
instead replace it with the term ‘unrelated 
finding’, ‘unanticipated result’ or some 
other suitable term.”
The definition of the word ‘incidental’ in the 
Merriam-Webster Dictionary is: “being likely to 
ensue as a chance or minor consequence, occur-
ring merely by chance or without intention or 
calculation” [101]. There is therefore absolutely 
nothing ‘incidental’ about what we did, as 
we actively and intentionally searched for the 
cause of our research subject’s anemia among 
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the millions of nucleotides that we sequenced, 
as well as spending much effort trying to prove 
causality for these particular variants, prior to 
then asking the research subject’s doctor to vali-
date the results in a CLIA-certified laboratory, 
before returning them to the research subject. 
This is simply not the same as a radiologist look-
ing at a film and immediately noticing a large 
mass in a place where it is not supposed to be. 
Radiologists spend many years perfecting their 
skills in pattern recognition, so that they can 
immediately recognize when something is dra-
matically wrong on a film. In fact, the human 
brain is exquisitely tuned for visual pattern 
recognition, as this skill was honed over mil-
lennia of evolution, allowing early humans to 
recognize very quickly when predators or other 
threatening things were in their immediate 
environment. Furthermore, radiologists typi-
cally self-select during medical school for strong 
visual–spatial skills, thus making it much more 
likely that they will be quite good at such pat-
tern recog nition tasks. Humans are simply not 
evolved for picking out mutations in millions 
or billions of nucleotides in a diploid genome, 
and there is simply nothing incidental about 
‘looking at the genomes’ and somehow ‘seeing’ 
causative mutations for diseases  unrelated to the 
research purpose. 
“Thus, the public and medical community 
will begin to understand that any result 
returned to a research subject must go 
through a rigorous confirmation of its 
medical actionability, so that people are not 
alarmed unnecessarily.”
Furthermore, there is nothing incidental or 
accidental about proving that a mutation actu-
ally causes a disease, either by itself (full pen-
etrance) or in combination with other mutations 
or environmnent (thus, likely partial pene-
trance). Currently, there are many studies being 
published that report rare variants found more 
in cases versus controls or as occurring de novo 
in cases, but this is only correlative evidence and 
actually proving that these mutations by them-
selves cause the disease requires biological exper-
imentation. Some authors are also defining inci-
dental findings as “fi ndings that are not explicitly 
related to the original research hypotheses (i.e., 
primary findings)” [14]. But, the continued use of 
the term ‘incidental finding’ threatens to trivial-
ize, at least in the mind of the general public, the 
amount of time and effort that goes into deter-
mining a real ‘unrelated finding’. In my informal 
polling of many members of the general pub-
lic, their general and consistent response when 
asked to define ‘incidental finding’ is that it is 
something that is somehow found by accident or 
coincidence (which of course reflects the actual 
definition of the word ‘incidental’). During the 
dozens of times in which I have consented peo-
ple to participate in our genomics research, at 
least half or more have asked whether we will 
return ‘any important results’ to them, and this 
fact is certainly supported by research involv-
ing focus groups’ opinions regarding return of 
research results [15–17]. That being said, over the 
past 2 years, I have never had a research subject 
inquire whether we will return any ‘incidental 
findings’ to them, and this is simply because the 
entire term is completely foreign and makes no 
sense to the general public (or to me) in this 
context. 
Conclusion
I realize that I am fighting an uphill battle 
against this term ‘incidental finding’, given 
that the term is already being pervasively 
quoted in many genetics research papers and 
commentaries. Nonetheless, I would suggest 
that the research community strongly consider 
getting rid of this term in the genomics world, 
and instead replace it with the term ‘unrelated 
finding’, ‘unanticipated result’ [18] or some other 
suitable term. This way, we will not inadver-
tently continue to belittle the amount of work 
and effort that ought to go into validating and 
proving causality for any unrelated findings 
obtained from whole exome and/or whole-
genome sequencing of human research subjects. 
Thus, the public and medical community will 
begin to understand that any result returned 
to a research subject must go through a rigor-
ous confirmation of its medical actionability, 
so that people are not alarmed un necessarily. 
This will become all the more important as 
whole-genome sequencing enters the clinic 
with the possible linking of CLIA-certified 
annotated genomes to medical records, as there 
will then be many such unrelated findings. In 
20–30 years, when we will likely have a detailed 
catalog of human genetic variation, I can imag-
ine that newborn babies will simply have a 
list of medically actionable ‘findings’ in their 
genome, allowing for proper genetic counsel-
ing and preventive measures to be implemented 
initially by their parents and then eventually by 
the growing child when they are old enough 
to understand their results. There is therefore 
nothing ‘incidental’ about this process.
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